Amicus Therapeutics (NASDAQ:FOLD) Downgraded to “Hold” Rating by StockNews.com

StockNews.com cut shares of Amicus Therapeutics (NASDAQ:FOLD) from a buy rating to a hold rating in a research report report published on Monday morning.

FOLD has been the subject of a number of other reports. Wells Fargo & Company reduced their price target on shares of Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating for the company in a research report on Thursday, February 20th. UBS Group upped their target price on shares of Amicus Therapeutics from $21.00 to $22.00 and gave the stock a “buy” rating in a research report on Friday. Cantor Fitzgerald reiterated an “overweight” rating and set a $21.00 price target on shares of Amicus Therapeutics in a research report on Wednesday, January 15th. Needham & Company LLC reissued a “hold” rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. Finally, The Goldman Sachs Group dropped their price target on shares of Amicus Therapeutics from $12.00 to $9.00 and set a “neutral” rating for the company in a research report on Friday. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $16.22.

Amicus Therapeutics Trading Down 2.1 %

Shares of FOLD opened at $6.53 on Monday. Amicus Therapeutics has a twelve month low of $6.20 and a twelve month high of $12.65. The stock has a market cap of $2.01 billion, a PE ratio of -36.28, a P/E/G ratio of 1.51 and a beta of 0.79. The company has a quick ratio of 2.42, a current ratio of 3.39 and a debt-to-equity ratio of 2.01. The business’s 50-day moving average price is $7.90 and its 200-day moving average price is $9.23.

Institutional Investors Weigh In On Amicus Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. Summit Investment Advisors Inc. boosted its position in Amicus Therapeutics by 4.4% during the fourth quarter. Summit Investment Advisors Inc. now owns 30,696 shares of the biopharmaceutical company’s stock valued at $289,000 after purchasing an additional 1,280 shares in the last quarter. Diversified Trust Co grew its position in shares of Amicus Therapeutics by 2.2% during the 1st quarter. Diversified Trust Co now owns 83,542 shares of the biopharmaceutical company’s stock valued at $682,000 after acquiring an additional 1,784 shares during the period. Xponance Inc. lifted its holdings in Amicus Therapeutics by 11.9% during the fourth quarter. Xponance Inc. now owns 21,216 shares of the biopharmaceutical company’s stock valued at $200,000 after purchasing an additional 2,249 shares in the last quarter. Covestor Ltd increased its position in shares of Amicus Therapeutics by 114.9% during the fourth quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company’s stock worth $41,000 after purchasing an additional 2,312 shares in the last quarter. Finally, Stephens Inc. AR lifted its stake in Amicus Therapeutics by 27.4% in the 1st quarter. Stephens Inc. AR now owns 13,655 shares of the biopharmaceutical company’s stock worth $111,000 after purchasing an additional 2,938 shares in the last quarter.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.